Hypersensitivity, Immediate: Clinical Trials

5704 completed, 886 unknown, 661 recruiting, 470 terminated. 2005 Not applicable, 1627 Phase 2, 1382 Phase 3, 881 Phase 1, 832 Phase 4.

By phase and status

Phase	Trials	Status
Not applicable	2005	Completed 1222, Unknown 292, Recruiting 174, Not yet recruiting 102, Terminated 86, Withdrawn 67, Active not recruiting 41, Enrolling by invitation 14, Suspended 7
Phase 2	1627	Completed 1137, Terminated 144, Recruiting 104, Unknown 78, Withdrawn 71, Active not recruiting 54, Not yet recruiting 31, Enrolling by invitation 8
Phase 3	1382	Completed 1049, Recruiting 74, Unknown 70, Terminated 63, Withdrawn 49, Active not recruiting 42, Not yet recruiting 26, Enrolling by invitation 8, Suspended 1
Phase 1	881	Completed 648, Terminated 73, Recruiting 52, Unknown 38, Withdrawn 30, Not yet recruiting 19, Active not recruiting 18, Enrolling by invitation 2, Suspended 1
Phase 4	832	Completed 590, Unknown 85, Terminated 59, Recruiting 32, Withdrawn 24, Active not recruiting 20, Not yet recruiting 20, Enrolling by invitation 2
Early Phase 1	58	Completed 36, Terminated 7, Unknown 6, Active not recruiting 4, Enrolling by invitation 3, Recruiting 1, Withdrawn 1

Follow Hypersensitivity, Immediate: new trials by email Literature Review of Hypersensitivity, Immediate trials Research Report on Hypersensitivity, Immediate

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients Skin Cleanser Combination No.1 - Atopic Dermatitis	Phase 4	Not yet recruiting	Boston Children's Hospital	100	2031-01-01	2026-03-10
Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis Ivermectin Pill - Atopic Dermatitis	Phase 2	Withdrawn	Stanford University		2030-12-01	2024-12-02
EFFECT OF AYURVEDA TREATMENT IN ALLERGIC RHINITIS AYURVEDA treatment protocol, Control(Citrizine 10mg) - Allergic Rhinitis (AR)	Not applicable	Not yet recruiting	Amrita Vishwa Vidyapeetham	104	2028-06-30	2026-06-04
Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis EC-18, Placebo EC-18 - Atopic Dermatitis	Phase 2	Not yet recruiting	Enzychem Lifesciences Corporation	150	2027-05-01	2026-08-28
Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age Abrocitinib, Placebo - Atopic Dermatitis	Phase 3	Not yet recruiting	Pfizer	90	2027-05-01	2026-09-16
Rapid Escalation Oral Immunotherapy to Achieve Remission in Children With Cashew Allergy cashew oral immunotherapy - Food Allergy in Children	Not applicable	Not yet recruiting	Murdoch Childrens Research Institute	25	2027-05-01	2026-11-03
Effect of Linvemastat in Patients With Partially Controlled Asthma (syMMPonia) linvemastat, Placebo - Asthma (Diagnosis), Pulmonary Function	Phase 2	Not yet recruiting	Foresee Pharmaceuticals Co., Ltd.	135	2027-03-01	2026-07-20
UNC Cashew Sublingual Immunotherapy Cashew sublingual immunotherapy, Placebo sublingual immunotherapy - Cashew Nut Allergy, Tree Nut Allergies	Phase 2	Not yet recruiting	University of North Carolina, Chapel Hill	45	2027-03-01	2026-10-20
Preventing Childhood Asthma Using Prophylactic House Dust Mite Allergen Immunotherapy HDM sublingual Immunotherapy, Placebo - Asthma, Allergy	Phase 2	Withdrawn	Boston Children's Hospital		2027-02-01	2024-11-26
Prevent Wheeze Trial Dexamethasone 0.6 mg/kilogram body weight single dose, Placebo - Lower Respiratory Tract Infection (LRTI), Recurrent Wheezing	Phase 4	Not yet recruiting	Norwegian University of Science and Technology	486	2027-02-01	2026-10-05
Changes in Symptom and Quality of Life in Patients With Uncontrolled Asthma Treated With Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Budesonide/Glycopyrronium/Formoterol fumarate metered dose inhaler - Asthma, Uncontrolled Asthma		Not yet recruiting	AstraZeneca	200	2027-01-29	2026-11-12
Educational Needs of Patients With Severe Asthma on Targeted Immunotherapies Initial assesment interwiew, Intake Interview with the Patient - Severe Asthma		Not yet recruiting	University Hospital, Angers	20	2027-01-04	2026-10-02
GOAt Milk Formula-based Ladder Versus Cow's Milk Ladder oral food challenge (OFC) - Food Allergy, Cow's Milk Protein Allergy	Not applicable	Not yet recruiting	Medical University of Warsaw	92	2027-01-02	2026-08-31
Educational Eczema Video Intervention in-clinic video intervention, at home video intervention - Eczema	Not applicable	Withdrawn	Boston Children's Hospital		2027-01-01	2026-10-19
Efficacy and Safety of Slow Release Dehydroepiandrosterone (DHEA ) Slow Release DHEA, Placebo - Asthma	Phase 2	Not yet recruiting	Indiana University	30	2027-01-01	2026-02-27
Nebulized Ketamine for Severe Asthma Attacks in Children Ketamine (1 mg/kg), Placebo - Asthma Acute, Exacerbation of Allergic Asthma	Phase 2	Not yet recruiting	Sultan Qaboos University	60	2027-01-01	2026-07-27
Immunotherapy for Curing Toddlers With Severe Food Allergy - a Paradigm Shift From Passive to Active Treatment With Multi-allergen Oral Immunotherapy OIT multiallergen powder, Placebo powder - Food Allergy in Children	Not applicable	Not yet recruiting	Odense University Hospital	80	2027-01-01	2026-10-27
Performance of the Basophil Activation Test in the Diagnosis of IgE-mediated Cow's Milk Allergy in Infants and Evaluation of Hydrolysate Allergenicity. Basophil activation test, quality of life questionnaire - Milk Allergy	Not applicable	Not yet recruiting	Odense University Hospital	100	2027-01-01	2026-10-28
Pulmonary Rehabilitation in African Countries Centre-based Pulmonary Rehabilitation, Community-based Pulmonary Rehabilitation - Chronic Respiratory Conditions	Not applicable	Not yet recruiting	University of Edinburgh	150	2027-01-01	2026-11-09
Sustainable Inhaler Prescribing in Intermediate Care Units Multidisciplinary inhaler optimization intervention - Pulmonary Disease, Chronic Obstructive (COPD), Asthma (Diagnosis)	Not applicable	Not yet recruiting	Consorci Sanitari de l'Alt Penedès i Garraf	110	2027-01-01	2026-11-12

Showing 20 of 8579. Sign in to see all of them.

Narrower conditions

Asthma (4474)  ·  Dermatitis, Atopic (1522)  ·  Rhinitis, Allergic (682)  ·  Hypersensitivity (447)  ·  Pulmonary Disease, Chronic Obstructive (444)  ·  Rhinitis, Allergic, Seasonal (384)  ·  Food Hypersensitivity (360)  ·  Eczema (358)  ·  Eosinophilic Esophagitis (234)  ·  Conjunctivitis, Allergic (197)  ·  Chronic Urticaria (194)  ·  Rhinitis, Allergic, Perennial (178)  ·  Angioedemas, Hereditary (169)  ·  Peanut Hypersensitivity (165)  ·  Lung Diseases (150)

Broader conditions

Immune System Diseases (8518)  ·  Hypersensitivity (8132)  ·  Respiratory Tract Diseases (5577)  ·  Respiratory Hypersensitivity (5561)  ·  Bronchial Diseases (4526)  ·  Lung Diseases, Obstructive (4445)  ·  Lung Diseases (4424)  ·  Skin and Connective Tissue Diseases (2107)  ·  Skin Diseases (2027)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1825)  ·  Genetic Diseases, Inborn (1789)  ·  Skin Diseases, Genetic (1547)  ·  Skin Diseases, Eczematous (1537)  ·  Dermatitis (1465)

Interventions

Fluticasone (237)  ·  Budesonide (200)  ·  montelukast (178)  ·  Albuterol (160)  ·  dupilumab (157)  ·  Omalizumab (153)  ·  Formoterol Fumarate (104)  ·  Mometasone Furoate (103)  ·  Beclomethasone (88)  ·  Fluticasone-Salmeterol Drug Combination (86)  ·  Salmeterol Xinafoate (80)  ·  Budesonide, Formoterol Fumarate Drug Combination (78)  ·  Blood Specimen Collection (63)  ·  benralizumab (57)  ·  fluticasone furoate (57)

Sponsors

AstraZeneca (345)  ·  GlaxoSmithKline (339)  ·  Novartis Pharmaceuticals (152)  ·  Organon and Co (149)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (102)  ·  Sanofi (96)  ·  Pfizer (87)  ·  National Heart, Lung, and Blood Institute (NHLBI) (76)  ·  Boehringer Ingelheim (71)  ·  Chiesi Farmaceutici S.p.A. (62)  ·  Regeneron Pharmaceuticals (56)  ·  Imperial College London (55)  ·  Johns Hopkins University (55)  ·  Teva Branded Pharmaceutical Products R&D, Inc. (55)  ·  University of North Carolina, Chapel Hill (54)

Countries

United States (3095)  ·  Germany (876)  ·  Canada (875)  ·  United Kingdom (824)  ·  France (612)  ·  China (566)  ·  Poland (522)  ·  Spain (491)  ·  Italy (426)  ·  Australia (325)  ·  Japan (324)  ·  Netherlands (314)  ·  South Korea (278)  ·  Hungary (263)  ·  Belgium (247)

Results publications

PMID 36472162, PMID 36326435, PMID 27881132, PMID 35636689, PMID 39393433, PMID 39588375, PMID 31319851, PMID 33006765, PMID 33826132, PMID 34389504, PMID 29400693, PMID 32926419, PMID 35691614, PMID 42162528, PMID 33217063, PMID 33305842, PMID 34406619, PMID 36255569, PMID 36723913, PMID 38127464, PMID 38814736, PMID 38896380, PMID 40993471, PMID 19001265, PMID 26704701, PMID 30954640, PMID 33165005, PMID 34037993, PMID 36408587, PMID 39104653, PMID 40028832, PMID 18331513, PMID 20818886, PMID 22329608, PMID 23312695, PMID 23878046, PMID 24184147, PMID 24712435, PMID 28065396, PMID 29174062, PMID 29536781, PMID 29656145, PMID 31066001, PMID 32180164, PMID 33453450, PMID 34098955, PMID 34142350, PMID 35061234, PMID 35342978, PMID 35567671

NIH funding

2018 (61), 2023 (48), 2016 (41), 2019 (41), 2015 (40), 2014 (38), 2017 (37), 2025 (32), 2009 (30), 2008 (18), 2004 (9), U10HL098115 (8), U10HL074212 (6), 2005 (5), P01HL107202 (5)